Hsbc Holdings PLC Raises Stock Position in Stryker Corporation $SYK

Key Points

• HSBC increased its Stryker position by 3.7% in the second quarter, adding 24,670 shares to hold 688,707 shares worth approximately $216.4 million. Institutional investors collectively own 77.09% of Stryker.
• Stryker reported quarterly EPS of $3.69, exceeding analyst expectations of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company issued full-year 2026 EPS guidance of $14.95–$15.10.
• The stock had a consensus “Moderate Buy” rating and an average analyst price target of $386.28, despite several recent target reductions. Stryker also declared a quarterly dividend of $0.88 per share, equivalent to a 1.2% annual yield.

Hsbc Holdings PLC lifted its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 3.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 688,707 shares of the medical technology company's stock after buying an additional 24,670 shares during the period. Hsbc Holdings PLC owned about 0.18% of Stryker worth $216,432,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in SYK. Gables Capital Management Inc. purchased a new position in shares of Stryker in the 2nd quarter worth approximately $25,000. Kilter Group LLC purchased a new stake in Stryker during the 2nd quarter valued at $25,000. Godfrey Financial Associates Inc. bought a new stake in Stryker in the fourth quarter worth $26,000. Sankala Group LLC bought a new stake in Stryker in the fourth quarter worth $26,000. Finally, United Financial Planning Group LLC purchased a new position in Stryker during the third quarter worth $27,000. Institutional investors own 77.09% of the company's stock.

Stryker Trading Down 0.1%

NYSE SYK opened at $302.92 on Monday. The stock has a market cap of $116.19 billion, a PE ratio of 31.39, a PEG ratio of 1.90 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.37. The company's 50-day moving average price is $328.84 and its 200-day moving average price is $329.48. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.03 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker's payout ratio is presently 36.48%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their target price on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Truist Financial upped their price target on shares of Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a report on Friday, July 31st. Leerink Partners reduced their price objective on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research report on Friday, June 5th. BTIG Research decreased their price objective on shares of Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a research note on Friday, July 31st. Finally, Citizens Jmp dropped their target price on Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Dylan Crotty sold 441 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares of the company's stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 over the last three months. 4.60% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source